Drug Profile
ELI 202
Alternative Names: ELI-202 opioidLatest Information Update: 28 Aug 2018
Price :
$50
*
At a glance
- Originator Elite Pharmaceuticals
- Class Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Opioid delta receptor antagonists; Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for phase-I development in Pain(In volunteers) in USA (PO)
- 09 Aug 2017 Elite Pharmaceuticals has patent protection relating to opioid abuse deterrent technology in Europe
- 12 Aug 2016 Pivotal Bio-equivalence development is ongoing in USA (Elite Pharmaceuticals Pipeline, August 2016)